Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94871777 | 9487177 | 7 | F | 201208 | 20160726 | 20130829 | 20160726 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-19140409 | BRISTOL MYERS SQUIBB | 26.76 | YR | F | Y | 46.70000 | KG | 20160726 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94871777 | 9487177 | 1 | PS | ABILIFY | ARIPIPRAZOLE | 1 | Oral | 12 MG, QD | Y | 21713 | 12 | MG | ORAL SOLUTION | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 94871777 | 9487177 | 1 | Psychomotor hyperactivity |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 94871777 | 9487177 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 94871777 | 9487177 | Foetal death | |
| 94871777 | 9487177 | Maternal exposure during pregnancy | |
| 94871777 | 9487177 | Off label use | |
| 94871777 | 9487177 | Uterine dilation and evacuation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 94871777 | 9487177 | 1 | 20120804 | 20120805 | 0 |